P-21 activated kinase 1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth

Cancer Letters

Volumn 317, Issue 1, 2012, Pages 65-71

  He, Hong ^a   Huynh, Nhi ^a   Liu, Kevin H ^a   Malcontenti Wilson, Cathy ^a   Zhu, Jin ^b   Christophi, Christopher ^a   Shulkes, Arthur ^a   Baldwin, Graham S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Catenin; CRC; PAK1

Indexed keywords

BETA CATENIN; MYC PROTEIN; P21 ACTIVATED KINASE 1; T CELL FACTOR 4 PROTEIN; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; ZINC FINGER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HT29 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856336786     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.014     Document Type: Article

References (31)

1. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
2. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 2007, 17:45-51.
3. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997, 275:1784-1787.
4. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
5. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., Tjon-Pon-Fong M., Moerer P., van den Born M., Soete G., Pals S., Eilers M., Medema R., Clevers H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
6. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62:6451-6455.
7. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 1988, 319:525-532.
8. H.J. Andreyev, A.R. Norman, D. Cunningham, J. Oates, B.R. Dix, B.J. Iacopetta, J. Young, T. Walsh, R. Ward, N. Hawkins, M. Beranek, P. Jandik, R. Benamouzig, E. Jullian, P. Laurent-Puig, S. Olschwang, O. Muller, I. Hoffmann, H.M. Rabes, C. Zietz, C. Troungos, C. Valavanis, S.T. Yuen, J.W. Ho, C.T. Croke, D.P. O'Donoghue, W. Giaretti, A. Rapallo, A. Russo, V. Bazan, M. Tanaka, K. Omura, T. Azuma, T. Ohkusa, T. Fujimori, Y. Ono, M. Pauly, C. Faber, R. Glaesener, A.F. de Goeij, J.W. Arends, S.N. Andersen, T. Lovig, J. Breivik, G. Gaudernack, O.P. Clausen, P.D. De Angelis, G.I. Meling, T.O. Rognum, R. Smith, H.S. Goh, A. Font, R. Rosell, X.F. Sun, H. Zhang, J. Benhattar, L. Losi, J.Q. Lee, S.T. Wang, P.A. Clarke, S. Bell, P. Quirke, V.J. Bubb, J. Piris, N.R. Cruickshank, D. Morton, J.C. Fox, F. Al-Mulla, N. Lees, C.N. Hall, D. Snary, K. Wilkinson, D. Dillon, J. Costa, V.E. Pricolo, S.D. Finkelstein, J.S. Thebo, A.J. Senagore, S.A. Halter, S. Wadler, S. Malik, K. Krtolica, N. Urosevic, Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study, Brit. J. Cancer 85 (2001) 692-696.
9. Zhang B., Ougolkov A., Yamashita K., Takahashi Y., Mai M., Minamoto T. Beta-Catenin and ras oncogenes detect most human colorectal cancer. Clin. Cancer Res. 2003, 9:3073-3079.
10. Janssen K.P., Alberici P., Fsihi H., Gaspar C., Breukel C., Franken P., Rosty C., Abal M., El Marjou F., Smits R., Louvard D., Fodde R., Robine S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131:1096-1109.
11. Mologni L., Dekhil H., Ceccon M., Purgante S., Lan C., Cleris L., Magistroni V., Formelli F., Gambacorti-Passerini C.B. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res. 2010, 70:7253-7263.
12. Kumar R., Gururaj A.E., Barnes C.J. p21-Activated kinases in cancer. Nat. Rev. Cancer 2006, 6:459-471.
13. Tang Y.Y., Shi J., Zhang L., Davis A., Bravo J., Warren A.J., Speck N.A., Bushweller J.H. Energetic and functional contribution of residues in the core binding factor beta (CBFbeta) subunit to heterodimerization with CBFalpha. J. Biol. Chem. 2000, 275:39579-39588.
14. He H., Hirokawa Y., Gazit A., Yamashita Y., Mano H., Kawakami Y., Kawakami, Hsieh C.Y., Kung H.J., Lessene G., Baell J., Levitzki A., Maruta H. The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol. Ther. 2004, 3:96-101.
15. Bokoch G.M. Biology of the p21-activated kinases. Annu. Rev. Biochem. 2003, 72:743-781.
16. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
17. He H., Shulkes A., Baldwin G.S. PAK1 interacts with beta-catenin and is required for the regulation of the beta-catenin signalling pathway by gastrins. Biochim. Biophys. Acta 2008, 1783:1943-1954.
18. G. Zhu, Y. Wang, B. Huang, J. Liang, Y. Ding, A. Xu, W. Wu, A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells, Oncogene (2011) 8. doi:10.1038/onc.2011.294 (Epub ahead of print).
19. Carter J.H., Douglass L.E., Deddens J.A., Colligan B.M., Bhatt T.R., Pemberton J.O., Konicek S., Hom J., Marshall M., Graff J.R. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin. Cancer Res. 2004, 10:3448-3456.
20. Li L.H., Zheng M.H., Luo Q., Ye Q., Feng B., Lu A.G., Wang M.L., Chen X.H., Su L.P., Liu B.Y. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int. J. Oncol. 2010, 37:951-962.
21. N. Huynh, K.H. Liu, G.S. Baldwin, H. He, P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways, Biochim. Biophys. Acta 1803 (2010) 1106-1113.
22. He H., Yim M., Liu K.H., Cody S.C., Shulkes A., Baldwin G.S. Involvement of G proteins of the Rho family in the regulation of Bcl-2-like protein expression and caspase 3 activation by Gastrins. Cell. Signal. 2008, 20:83-93.
23. Harun N., Nikfarjam M., Muralidharan V., Christophi C. Liver regeneration stimulates tumor metastases. J. Surg. Res. 2007, 138:284-290.
24. Wong S.C., Lo E.S., Lee K.C., Chan J.K., Hsiao W.L. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin. Cancer Res. 2004, 10:1401-1408.
25. Spaderna S., Schmalhofer O., Hlubek F., Berx G., Eger A., Merkel S., Jung A., Kirchner T., Brabletz T. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131:830-840.
26. Verma U.N., Surabhi R.M., Schmaltieg A., Becerra C., Gaynor R.B. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 2003, 9:1291-1300.
27. Mariadason J.M., Bordonaro M., Aslam F., Shi L., Kuraguchi M., Velcich A., Augenlicht L.H. Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res. 2001, 61:3465-3471.
28. Luo F., Brooks D.G., Ye H., Hamoudi R., Poulogiannis G., Patek C.E., Winton D.J., Arends M.J. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int. J. Exp. Pathol. 2009, 90:558-574.
29. Munemitsu S., Albert I., Souza B., Rubinfeld B., Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. USA 1995, 92:3046-3050.
30. Ilyas M., Tomlinson I.P., Rowan A., Pignatelli M., Bodmer W.F. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA 1997, 94:10330-10334.
31. Schmalhofer O., Brabletz S., Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metast. Rev. 2009, 28:151-166.